Why Orexigen’s Contrave May Win In The End
Executive Summary
The biotech finally gleaned an FDA approval for its obesity pill Contrave and now faces the hurdle of commercialization, but plans to profit by the lessons from its competitors’ missteps.
You may also be interested in...
Novo Nordisk’s Liraglutide Gets Panel Nod For Weight Management
Advisory committee members are generally comfortable with use of the GLP-1 receptor agonist in the first-line setting, suggesting that a second-line treatment restriction in diabetes could be lifted.
Orexigen Thinks Contrave On The Verge Of Approval, Again
The biotech once again faces an FDA approval decision for its bupropion/naltrexone obesity combo, after a long and costly cardiovascular outcomes trial has kept the drug off the market.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.